22nd Century To Secure $3M Via Registered Direct Offering Priced Above Market
22nd Century Group, Inc.
Cannabis Company Ayr Wellness Loans Money From Needham Bank To Support Its Cultivation Facility
AYR Wellness Inc. (OTCQX: AYRWF) (CSE:AYR.A) has closed on a $40 million refinancing and upsizing of its existing mortgage for its Gainesville cultivation facility, with Needham Bank.
LEEF Brands Teams Up With Farming First To Enhance Its Cannabis Supply Chain
LEEF Brands, Inc. (OTCQB: LEEEF) (CSE:LEEF) entered into a strategic partnership with Farming First Holdings, LLC.
Incannex Approved For Bioavailability Clinical Trial For Dronabinol-Based Drug For Treatment Of Obstructive Sleep Apnea
Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) has received approval from Bellberry Human Research Ethics Committee to commence a bioavailability/bioequivalence (‘BA/BE’) clinical trial on IHL-42X, the company’s proprietary drug prod
NFL-Funded Study: CBD Or Non-Invasive Vagal Nerve Stimulation – Which Is Better To Alleviate Concussion Symptoms
electroCore, Inc.’s (NASDAQ: ECOR) gammaCore non-invasive vagus nerve stimulation (“nVNS”) has been selected to be a part of studies on effects of cannabinoids and alternative care on athlete pain management and perfor
MedMen Appoints Ellen Deutsch As CEO And Amit Pandey As CFO
MedMen Enterprises Inc. (OTCQX: MMNFF) (CSE:MMEN) appointed Ellen Deutsch as CEO, effective immediately, and Amit Pandey as CFO, effective July 24th.
IGC Pharma Secures $3M Via Private Placement
IGC Pharma, Inc. (AMEX:IGC) announced a strategic investment from four investment funds managed by Bradbury Asset Management (Hong Kong) Limited, an asset management firm with over $2 billion in managed assets.
Skye Completes Production Of Cannabinoid Based Drug In Preparation For Glaucoma Clinical Trial
Skye Bioscience, Inc. (OTCQB: SKYE), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma and ocular hypertension, announced that its contract manufacturer, NextPharma Oy, in Finland, has completed production of placebo and
BZAM Sells Galaxie And Amends Credit Agreement
BZAM Ltd. (OTCQX: BZAMF) (CSE:BZAM) completed the disposal of Galaxie Brands Corporation via a share purchase agreement whereby it will sell all of the issued and outstanding shares in the capital of Galaxie to a third party for $556,522 less usual post closing adjustments.